Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label secukinumab in plaque psoriasis with inadequate response to cyclosporine A
jRCT1080222997Phase 4
- Sponsor
- Novartis
- Start
- Oct 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of secukinumab in plaque psoriasis, sponsored by Novartis.
02
Drugs
secukinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on jRCT1080222997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080222997.